No Needles
Compounded oral semaglutide tablets
GLP-1 Medication

Contains semaglutide (compounded; not FDA-approved)

Compounded semaglutide oral tablet — needle-free daily option

Compounded Oral Semaglutide

Needle-free GLP-1 option — daily oral tablet

Starting at$149

Starting at $149 for your first month; subscription auto-renews monthly at the standard plan rate until cancelled. Includes provider consultations and medication. Cancel anytime. See full pricing details.

Compounded medication: Prepared by state-licensed sterile compounding pharmacies. Individual results may vary. See full Safety Information.
In Stock — Ready to Ship
Sublingual tablet
|Daily
30-day consultation-fee refund (medication non-refundable per policy)Review us on TrustpilotTake the Quiz →
No insurance requiredCancel anytimeFree discreet shipping

Available in 39 U.S. states · Licensed providers in your state

No credit card required. If you don't qualify, you won't be charged.

About This Treatment

A sublingual tablet form of semaglutide for patients who prefer not to inject. Same GLP-1 receptor agonist action in a convenient daily dose.

How It Works

GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves blood sugar control.

Key Benefits

  • No injections required
  • Convenient daily tablet
  • Reduces appetite and cravings
  • GLP-1 receptor agonist mechanism
  • Easy to take at home

What's Included

  • Licensed provider consultation
  • Personalized dosing protocol
  • Compounded oral semaglutide tablets
  • Monthly medication shipment
  • Free discreet shipping
  • HIPAA-secure messaging with care team
  • Dosage adjustments as needed
  • 24/7 patient support
  • Cancel anytime

Medically reviewed by licensed healthcare providers in our clinical partner network · Last reviewed: April 2026

FDA Boxed Warning — Thyroid C-Cell Tumors

GLP-1 receptor agonists (including semaglutide and tirzepatide) caused thyroid C-cell tumors in rodents. It is unknown whether these medications cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC and symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).

See full Safety Information before starting therapy.

Important information

Not Sure Which Treatment Is Right for You?

Take our free assessment and a licensed provider will recommend the best option based on your health profile and goals.

Take the Quiz →